UK Biotech still going strong at the start of 2019
The UK Biotech industry is showing a strong outlook at the start of 2019, despite the uncertainties of Brexit.
Read More
Tag: UK BioIndustry Association
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
